RESUMEN
BACKGROUND: There are limited data available regarding the impact of ofatumumab, an anti-CD20 B-cell-depleting monoclonal antibody for relapsing multiple sclerosis (RMS), on vaccination response. The study objective was to assess humoral immune response (HIR) to non-live coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination in patients with RMS treated with ofatumumab. METHODS: This was an open-label, single-arm, multicenter, prospective pilot study of patients with RMS aged 18-55 years who received 2 or 3 doses of a COVID-19 mRNA vaccine after ≥1 month of subcutaneous ofatumumab (20 mg/month) treatment. The primary endpoint was the proportion of patients achieving HIR, as defined by local laboratory severe acute respiratory syndrome coronavirus-2 qualitative immunoglobulin G assays. Assay No. 1 was ≥14 days after the second or third vaccine dose. Assay No. 2 was 90 days thereafter. RESULTS: Of the 26 patients enrolled (median [range] age: 42 [27-54] years; median [range] ofatumumab treatment duration: 237 [50-364] days), HIR was achieved by 53.9% (14/26; 95% CI: 33.4 - 73.4%) at Assay No. 1 and 50.0% (13/26; 95% CI: 29.9 - 70.1%) at Assay No. 2. Patients who received 3 vaccine doses had higher HIR rates (Assay No. 1: 70.0% [7/10]; Assay No. 2: 77.8% [7/9]) than those who received 2 doses (Assay No. 1: 46.7% [7/15]; Assay No. 2: 42.9% [6/14]). Of patients aged <40 years without previous anti-CD20 therapy, HIR was achieved by 90.0% (9/10) at Assay No. 1 and 75.0% (6/8) at Assay No. 2. No serious adverse events were reported. CONCLUSION: Patients with RMS treated with ofatumumab can mount HIRs following COVID-19 vaccination. A plain language summary, infographic and a short video summarizing the key results are provided in supplementary material. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT04847596 (https://clinicaltrials.gov/ct2/show/NCT04847596).
Asunto(s)
COVID-19 , Esclerosis Múltiple , Humanos , Adulto , Vacunas contra la COVID-19 , COVID-19/prevención & control , Inmunidad Humoral , Proyectos Piloto , Estudios Prospectivos , Recurrencia , Vacunas de ARNm , Anticuerpos AntiviralesRESUMEN
Recombinant interferon (IFN) ß-1b was approved by the US Food and Drug Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in 1993. Since that time, clinical trials and real-world observational studies have demonstrated the effectiveness of IFN therapies. The pivotal intramuscular IFN ß-1a phase III trial published in 1996 was the first to demonstrate that a DMT could reduce accumulation of sustained disability in MS. Patient adherence to treatment is higher with intramuscular IFN ß-1a, given once weekly, than with subcutaneous formulations requiring multiple injections per week. Moreover, subcutaneous IFN ß-1a is associated with an increased incidence of injection-site reactions and neutralizing antibodies compared with intramuscular administration. In recent years, revisions to MS diagnostic criteria have improved clinicians' ability to identify patients with MS and have promoted the use of magnetic resonance imaging (MRI) for diagnosis and disease monitoring. MRI studies show that treatment with IFN ß-1a, relative to placebo, reduces T2 and gadolinium-enhancing lesions and gray matter atrophy. Since the approval of intramuscular IFN ß-1a, a number of high-efficacy therapies have been approved for MS, though the benefit of these high-efficacy therapies should be balanced against the increased risk of serious adverse events associated with their long-term use. For some subpopulations of patients, including pregnant women, the safety profile of IFN ß formulations may provide a particular benefit. In addition, the antiviral properties of IFNs may indicate potential therapeutic opportunities for IFN ß in reducing the risk of viral infections such as COVID-19.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Interferón beta-1a/uso terapéutico , Esclerosis Múltiple/tratamiento farmacológico , Antivirales/uso terapéutico , Humanos , Inyecciones Intramusculares , Esclerosis Múltiple/diagnóstico por imagen , Esclerosis Múltiple/fisiopatología , SARS-CoV-2 , Resultado del Tratamiento , Tratamiento Farmacológico de COVID-19RESUMEN
Interferon beta therapies have been effective in the treatment of relapsing forms of multiple sclerosis for over 2 decades. These therapies have varying routes and schedules of administration but broadly similar clinical and radiologic efficacy. The most commonly reported adverse effects are flu-like symptoms and injection site reactions. The most recent addition to the class is peginterferon beta-1a, which is administered subcutaneously every 2 weeks. Although clinically stable patients with multiple sclerosis may switch between platform therapies (such as interferons) based on tolerability or personal preference, few studies have explored the outcomes of switching. Herein I present 3 cases of patients who either initiated therapy with peginterferon beta-1a or switched from another interferon and had positive outcomes. With appropriate patient education and expectation setting regarding potential flu-like symptoms and injection-site reactions, peginterferon beta-1a may be a beneficial alternative for patients who prefer less frequent injections.
Asunto(s)
Factores Inmunológicos/farmacología , Interferón beta-1a/farmacología , Interferón beta/farmacología , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Polietilenglicoles/farmacología , Adulto , Anciano , Sustitución de Medicamentos , Femenino , Humanos , Factores Inmunológicos/administración & dosificación , Interferón beta-1a/administración & dosificación , Interferón beta/administración & dosificación , Persona de Mediana Edad , Polietilenglicoles/administración & dosificaciónRESUMEN
A nondemented, 55-year-old woman with a 20-year history of relapsing-remitting multiple sclerosis (MS) recently began having significant difficulties performing her job after several years of successful employment. While the patient acknowledged that others considered her job performance as being below standards, she did not subjectively experience any change in her cognitive functioning that would negatively impact job performance. She had no explanation as to why her job performance was now considered unsatisfactory. She also appeared to be in no distress over her situation. Was the patient's unawareness a form of anosognosia or psychological denial of her clinical condition? We provide neuropsychological, neuroimaging, and behavioral descriptions of the patient that suggest that the underlying disturbance appeared to be a neuropsychologically based, impaired self-awareness (ISA). Clinical suggestions are provided for distinguishing between ISA and denial of disability (DD) in MS patients.